Dyne therapeutics news
WebNov 2, 2024 · Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy August … WebApr 11, 2024 · On average, analysts predict that Dyne Therapeutics will post -3.23 EPS for the current year. Insider Activity at Dyne Therapeutics. In related news, insider Jonathan Mcneill sold 10,000 shares of the company's stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of …
Dyne therapeutics news
Did you know?
WebApr 11, 2024 · Ashburn, Virginia, United States, April 11, 2024 (GLOBE NEWSWIRE) -- Domo Tactical Communications (DTC), a CODAN company, has entered into a supply … WebApr 11, 2024 · A high-level overview of Dyne Therapeutics, Inc. (DYN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …
WebDyne Therapeutics 7,996 followers 1y Report this post Report Report. Back ... WebScientist I - Molecular Analyses and Electrophysiology; Translational Therapeutics; Traumatic Brain. Bethesda, Maryland; To be discussed in initial interview. Henry M. …
WebApr 11, 2024 · Dyne Therapeutics Trading Down 6.0 %. DYN stock opened at $8.82 on Tuesday. The firm has a 50 day moving average of $12.59 and a 200-day moving average of $12.09. The firm has a market ... WebDec 15, 2024 · The Trade: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes acquired a total of 934,581 shares at an average price of $10.70. To acquire these shares, it cost around $10 million. What ...
WebJan 19, 2024 · Dyne Therapeutics, Inc. (NASDAQ: DYN) is a Waltham, Massachusetts based early clinical-stage biopharmaceutical concern focused on the development of oligonucleotide (small bits of RNA or DNA ...
WebApr 11, 2024 · Insider Activity at Dyne Therapeutics. In related news, insider Jonathan Mcneill sold 10,000 shares of the company’s stock in a transaction dated Wednesday, … highlights from the cavs gameWebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … highlights from the book of 2 kingsWebMar 20, 2024 · WALTHAM, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on … small plywood sailboatsWebView the latest Dyne Therapeutics Inc. (DYN) stock price, news, historical charts, analyst ratings and financial information from WSJ. highlights from the nascar race yesterdayWebMar 2, 2024 · - Data Anticipated in the Second Half of 2024 from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD - WALTHAM, Mass., March 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life … highlights from the grammysWebGet the latest Dyne Therapeutics Inc (DYN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment … highlights from the oscars 2022WebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … small pneumatic wheels and tyres